ArticleLiver international : official journal of the International Association for the Study of the Liver2025
A Conserved FABP5
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artesunate Targets MBL2 to Modulate the TLR4/NRF2/HO‑1 Axis and Ameliorate Podophyllotoxin‑Induced Liver Injury.Drug design, development and therapy · 2026Article
- Transcriptomic analysis identifies FABP5 as a candidate regulator of lipid accumulation in metabolic dysfunction-associated fatty liver disease.Frontiers in endocrinology · 2026Article
- A Conserved FABP5Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Immunological mechanisms underlying fibrotic diseases via single-cell technologies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
BACKGROUND AND
aimsThe relationship between chronic liver disease and liver cancer remains poorly understood, and treatment options for advanced liver disease remain limited. This study aims to elucidate the dynamic evolution of cellular and molecular alterations from normal liver to diseased liver.
methodsSingle-cell RNA sequencing was performed to profile the dynamic cellular variations from normal liver to diseased liver. Bioinformatics analyses were employed to assess tumour heterogeneity and the evolution of tumour microenvironment. Molecular biology validations were performed to investigate the findings.
resultsThrough single-cell RNA sequencing, we constructed a human liver landscape consisting of more than 130 000 single cells, from normal, cirrhotic tissue, primary liver cancer and paired adjacent tissues. We profiled both inter- and intra-tumour heterogeneity of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. A dual role of the pro-fibrosis and pro-carcinogenesis FABP5
conclusionsOur findings provide insights into the evolution from chronic liver disease to liver cancer. These insights will contribute to the development of novel cell subset-based therapeutics based on immunotherapy and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.